Kallyope operates as a biotechnology firm whose mission is to discover and develop oral agents that are both effective and easy to use. The company employs a combination of technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics. Kallyope's in-depth understanding of gut-brain biology allows it to provide the healthcare sector with therapeutics designed to enhance human health.

Investors Include:

William Gates, Bill Gates, Lux Capital, Euclidean Capital, Illumina Ventures, Mubadala Investment Company, The Column Group, Two Sigma Ventures, Illumina, Anthony Evnin, Columbia Technology Ventures, Bill & Melinda Gates Foundation, DNS Capital, Casdin Capital, Polaris Partners, Alexandria Venture Investments, StepStone Group, Tao Capital Partners.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund